TREA

90151432 - ÆTERNA ZENTARIS

Follow

Information

  • Trademark
  • 90151432
  • Serial Number
    90151432
  • Registration Number
    6400616
  • Filing Date
    September 01, 2020
    4 years ago
  • Registration Date
    June 29, 2021
    3 years ago
  • Transaction Date
    June 29, 2021
    3 years ago
  • Status Date
    June 29, 2021
    3 years ago
  • Published for Opposition Date
    April 13, 2021
    3 years ago
  • Location Date
    June 29, 2021
    3 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    JACKSON, STEVEN W
  • Attorney Docket Number
    USTF10166878
    Attorney Name
    Victoria Friedman
    Law Office Assigned Location Code
    L70
  • Owners
Information
Mark Drawing Code
3000
Mark Identification
ÆTERNA ZENTARIS
Case File Statements
  • CC0000: The color(s) azure and dark lime green is/are claimed as a feature of the mark.
  • DM0000: The mark consists of a stylized wavy line in the shape of a sideways infinity symbol on a slight tilt to the right with the tail ends in azure and the middle swoop in dark lime green followed by the word "ÆTERNA" in thin dark lime green letters above the word "ZENTARIS" in thick azure letters.
  • GS0051: Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic products, conjugated or not, for the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancer, hormonal tumors, or hormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, comprising growth hormone secretagogues, ghrelin receptor agonists, ghrelin receptor antagonists, ghrelin mimetics, growth hormone analogues, growth hormone fusion proteins, growth hormone releasing hormone analogues, auto immune modulating proteins, therapeutic antibodies, small molecule kinase inhibitors, phospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical products, comprising small molecule kinase inhibitors, phospholipids, therapeutic antibodies, natural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications
Case File Event Statements
  • 6/29/2021 - 3 years ago
    17 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 4/13/2021 - 3 years ago
    16 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/13/2021 - 3 years ago
    15 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 3/24/2021 - 3 years ago
    14 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 3/10/2021 - 3 years ago
    13 - ELECTRONIC RECORD REVIEW COMPLETE Type: FIXD
  • 3/5/2021 - 3 years ago
    12 - ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Type: ERRR
  • 3/1/2021 - 3 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/26/2021 - 3 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/26/2021 - 3 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/26/2021 - 3 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/12/2021 - 4 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/12/2021 - 4 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 1/12/2021 - 4 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/6/2021 - 4 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/7/2020 - 4 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 10/6/2020 - 4 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 9/4/2020 - 4 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP